NCT02662751 Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
| NCT ID | NCT02662751 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2019-10-21 |
| Primary Completion | 2026-06-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 260 participants in total. It began in 2019-10-21 with a primary completion date of 2026-06-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.
Eligibility Criteria
Inclusion Criteria: * The patient was informed about the implementation of the study, its objectives, constraints and patient rights * The patient has given free and informed consent and signed the consent * Patient affiliated with or beneficiary of a health insurance plan * Patient available for 36 months of follow-up * The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage Exclusion Criteria: * The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study. * Patient under guardianship or judicial protection * Refusal to sign the consent * Inability to correctly inform the patient or his/her trusted person about the study * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study * Known allergy to contrast medium or severe allergy to iodine * Known active malignancy or history of cancer treatment * The patient has already undergone a full body scanner in the previous three months * Renal failure with creatinine clearance below 60 ml / min * Monoclonal immunoglobulin * History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia) * Emergency situations that hamper the planned course of the study
Contact & Investigator
Francesco Macri, MD
STUDY DIRECTOR
Centre Hospitalier Universitaire de Nīmes
Frequently Asked Questions
Who can join the NCT02662751 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02662751 currently recruiting?
Yes, NCT02662751 is actively recruiting participants. Contact the research team at francesco.macri@chu-nimes.fr for enrollment information.
Where is the NCT02662751 trial being conducted?
This trial is being conducted at Montpellier, France, Nîmes, France.
Who is sponsoring the NCT02662751 clinical trial?
NCT02662751 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Francesco Macri, MD at Centre Hospitalier Universitaire de Nīmes. The trial plans to enroll 260 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.